Discover OraVerse, a breakthrough that reverses unwanted lingering soft tissue anesthesia after routine dental procedures.
First and only local anesthesia reversal agent to restore sensations twice as fast* after an injection.
Item #99210 – Box containing 1 blister of 10 x 1.7ml glass cartridges
In clinical trials, the most common adverse events with OraVerse (phentolamine mesylate) vs. control were post procedural pain (6% vs. 6%), injection site pain (5% vs. 4%), tachycardia (5% vs. 6%), bradycardia (2% vs. 0.3%) and headache (3% vs. 4%). Following parenteral use of phentolamine in non-dental indications, myocardial infarction and cerebrovascular spasm and occlusion have been reported, usually in association with marked hypotensive episodes producing shock-like states. Although such effects are uncommon with OraVerse, clinicians should be alert to the signs and symptoms of tachycardia and cardiac arrhythmias, particularly in patients with a history of cardiovascular disease, as these symptoms may occur with the use of phentolamine or other alpha-adrenergic blocking agents.
Learn more about OraVerse™
1st and only local anesthesia reversal agent
Restores sensations twice as fast* after an injection
No natural rubber latex - 0% methylparabens
None of the ingredients of our product OraVerse™ are an evident source of alcohol.
None of the ingredients of our product OraVerse™ are an evident source of gluten.
None of the ingredients of our product OraVerse™ are an evident source of peanut, soy or nut.
Sign up now and get an exclusive access to: